Top Midday Gainers

MT Newswires Live06-04

Structure Therapeutics (GPCR) shares soared about 78% amid heavy trading after the company reported Monday positive 12-week topline obesity data from its phase 2a trial of GSBR-1290, with results showing a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2%.

Over 9.2 million shares traded intraday versus a daily average of roughly 604,000.

Microbot Medical (MBOT) said Monday that it signed definitive agreements to sell about 1.57 million shares at $1.50 apiece in a registered direct offering. It will also issue series F preferred investment options in a concurrent placement.

Shares soared 50% as intraday trading volume catapulted to more than 143.5 million versus a daily average of about 96,000.

Bio-Path (BPTH) shares soared after the company reported positive interim results from a phase 2 study of prexigebersen in combination with decitabine and venetoclax to treat acute myeloid leukemia.

Shares surged 41% as intraday trading volume shot to over 54.1 million from a daily average of about 1.46 million.

Price: 61.11, Change: +26.91, Percent Change: +78.69

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2440150094?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-04 01:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2440150094","market":"us","top_or_hot":-1,"title":"Top Midday Gainers","media":"MT Newswires Live","content":"<html><body><p> Structure <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (GPCR) shares soared about 78% amid heavy trading after the company reported Monday positive 12-week topline obesity data from its phase 2a trial of GSBR-1290, with results showing a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2%.</p><p>Over 9.2 million shares traded intraday versus a daily average of roughly 604,000.</p><p>Microbot Medical (MBOT) said Monday that it signed definitive agreements to sell about 1.57 million shares at $1.50 apiece in a registered direct offering. It will also issue series F preferred investment options in a concurrent placement.</p><p>Shares soared 50% as intraday trading volume catapulted to more than 143.5 million versus a daily average of about 96,000.</p><p>Bio-Path (BPTH) shares soared after the company reported positive interim results from a phase 2 study of prexigebersen in combination with decitabine and venetoclax to treat acute myeloid leukemia.</p><p>Shares surged 41% as intraday trading volume shot to over 54.1 million from a daily average of about 1.46 million.</p><p>Price: 61.11, Change: +26.91, Percent Change: +78.69</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Gainers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Gainers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-04 01:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Structure Therapeutics (GPCR) shares soared about 78% amid heavy trading after the company reported Monday positive 12-week topline obesity data from its phase 2a trial of GSBR-1290, with results ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GPCR","symbol_name":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2440150094","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2440150094","pubTimestamp":1717437357,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Structure Therapeutics  shares soared about 78% amid heavy trading after the company reported Monday positive 12-week topline obesity data from its phase 2a trial of GSBR-1290, with results showing a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2%.Over 9.2 million shares traded intraday versus a daily average of roughly 604,000.Microbot Medical  said Monday that it signed definitive agreements to sell about 1.57 million shares at $1.50 apiece in a registered direct offering. It will also issue series F preferred investment options in a concurrent placement.Shares soared 50% as intraday trading volume catapulted to more than 143.5 million versus a daily average of about 96,000.Bio-Path  shares soared after the company reported positive interim results from a phase 2 study of prexigebersen in combination with decitabine and venetoclax to treat acute myeloid leukemia.Shares surged 41% as intraday trading volume shot to over 54.1 million from a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GPCR":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","BK4007":"制药","BPTH":"Bio-Path Holdings, Inc.","BK4139":"生物科技","BK4082":"医疗保健设备","MBOT":"Microbot Medical Inc"},"translate_title":"午盘涨幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BPTH":0.9,"GPCR":0.9,"MBOT":0.9},"content_text":"Structure Therapeutics (GPCR) shares soared about 78% amid heavy trading after the company reported Monday positive 12-week topline obesity data from its phase 2a trial of GSBR-1290, with results showing a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2%.Over 9.2 million shares traded intraday versus a daily average of roughly 604,000.Microbot Medical (MBOT) said Monday that it signed definitive agreements to sell about 1.57 million shares at $1.50 apiece in a registered direct offering. It will also issue series F preferred investment options in a concurrent placement.Shares soared 50% as intraday trading volume catapulted to more than 143.5 million versus a daily average of about 96,000.Bio-Path (BPTH) shares soared after the company reported positive interim results from a phase 2 study of prexigebersen in combination with decitabine and venetoclax to treat acute myeloid leukemia.Shares surged 41% as intraday trading volume shot to over 54.1 million from a daily average of about 1.46 million.Price: 61.11, Change: +26.91, Percent Change: +78.69","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2440150094"}